You are here

Roche

Personal turf is ‘out,’ community workplaces are ‘in’ at the new Roche neighborhood

Personal turf is ‘out,’ community workplaces are ‘in’ at the new Roche neighborhood

Endpoints

Flag link:

An analysis of 2017 first half for pharmaceutical industry

An analysis of 2017 first half for pharmaceutical industry

GoInPharma

pharma industry

Bristol-Myers Squibb

Flag link:

Lawmakers dig into 'skyrocketing' MS costs with probe into 7 drugmakers

Lawmakers dig into 'skyrocketing' MS costs with probe into 7 drugmakers

Fierce Pharma

multiple sclerosis

Teva Pharmaceutical

Flag link:

Roche, Mimetas develop “gut-on-a-chip” tech for drug-testing

Roche, Mimetas develop “gut-on-a-chip” tech for drug-testing

Drug Delivery Business News

drug development

Flag link:

New target could yield treatment for Alzheimer's, ALS and more

New target could yield treatment for Alzheimer's, ALS and more

Fierce Biotech

drug development

Alzheimer's disease

Flag link:

Drug developers face increasingly risky tightrope walk between top-line results and hard data

Drug developers face increasingly risky tightrope walk between top-line results and hard data

Endpoints

drug development

clinical trials

late stage data

Flag link:

Pharma's giants, new and old, tell more tales than their numbers show

Pharma's giants, new and old, tell more tales than their numbers show

Fierce Pharma

Bristol-Myers Squibb

Flag link:

The 2017 report card so far: Big Biotech largely trading up as pharma posts mixed results

The 2017 report card so far: Big Biotech largely trading up as pharma posts mixed results

Fierce Pharma

Bristol-Myers Squibb

Flag link:

Dermira Commits $135M for Global Rights to Roche Eczema Drug

Dermira Commits $135M for Global Rights to Roche Eczema Drug

Xconomy

Flag link:

As Roche wades biosimilar waters, more competitors circle Herceptin

As Roche wades biosimilar waters, more competitors circle Herceptin

BioPharma Dive

Flag link:

FDA advances two more Herceptin biosims—this time from Amgen and Teva—as Roche braces for impact

FDA advances two more Herceptin biosims—this time from Amgen and Teva—as Roche braces for impact

Fierce Pharma

Teva Pharmaceutical

Flag link:

Roche raises 2017 outlook after H1 beat

Roche raises 2017 outlook after H1 beat

CNBC

Flag link:

Biotechs Find Strength In Numbers In Treating Multiple Sclerosis

Biotechs Find Strength In Numbers In Treating Multiple Sclerosis

Investors Business Daily

multiple sclerosis

Flag link:

Diabetes drugmakers partner with mobile startups to boost patient engagement

Diabetes drugmakers partner with mobile startups to boost patient engagement

Medical Marketing and Media

Flag link:

Poor test results for Roche cloud growth prospects

Poor test results for Roche cloud growth prospects

Yahoo/Reuters

Flag link:

5 Big Pharma Stocks With the Best Drug Pipelines

5 Big Pharma Stocks With the Best Drug Pipelines

Motley Fool

Gilead Sciences

Flag link:

The biosimilar pack is growing around Roche’s all-star trio, looking to rip into a $21B franchise

The biosimilar pack is growing around Roche’s all-star trio, looking to rip into a $21B franchise

Endpoints

Flag link:

Shire blasts rival Roche for its “misleading” case for hemophilia trailblazer emicizumab

Shire blasts rival Roche for its “misleading” case for hemophilia trailblazer emicizumab

Motley Fool

Flag link:

Why Drugmakers Aren’t Sweating the Next Wave of Patent Losses

Why Drugmakers Aren’t Sweating the Next Wave of Patent Losses

Bloomberg

Flag link:

Prescribed Reading: I/O is the only game in town

Prescribed Reading: I/O is the only game in town

BioPharma Dive

immuno-oncology

Endo International

Vertex Pharmaceuticals

Bristol-Myers Squibb

Flag link: